机构:[1]The Second Clinical Medical College of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China广东省中医院[2]Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China[3]The Academy of Integrative Medicine of Fudan University, Shanghai, China[4]Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China
Hormone therapy (HT) has been used in postmenopausal women for decades in clinical practice. With further analysis and newer studies, the benefits and risks of HT have been repeatedly verified and discussed. HT is recommended for the treatment of vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM) and the prevention of osteoporosis. However, the precise association between HT and the risks of cardiovascular diseases, venous thromboembolism, neurodegenerative diseases, breast cancer, and endometrial cancer remains controversial. Therefore, determining how to take advantage of and control the risks of HT by adjusting the initiation time, regimen, and duration is crucial. Recent studies have indicated that HT is not related to the risk of all-cause, cardiovascular, or breast cancer mortality although it might increase the incidence of some chronic diseases. For symptomatic postmenopausal women under the age of 60 without contraindications, early initiation of HT is safe and probably has a mortality benefit over the long term. Initiating HT close to menopause at the lowest effective dose is more likely to have maximal benefits and the lowest risks. Transdermal and vaginal HT may have a lower risk, but recent evidence suggests additional clinical benefits of oral HT formulations in relieving VMS and preventing osteoporosis. The pooled cohort risk equation for atherosclerotic cardiovascular disease (ASCVD) and the free app named Menopro can be used to perform individual risk assessments. In addition, Chinese herbal medicines have benefits in alleviating hot flashes, depression, and menopausal symptoms, although further data are needed to strongly support their efficacy. Acupuncture and electroacupuncture have definite efficacy in the treatment of postmenopausal symptoms with few adverse effects, so they are a reasonable option as an alternative therapy for high-risk women. This review discusses the history of, guidelines on, and strategies for HT in order to make suggestions based on the most up-to-date evidence for the management of postmenopausal women.
基金:
2018 Program to Guide Medicine ("Yixue Yindao") of the Shanghai Municipal Science and Technology Commission [18401902200]; Scientific and Technological Innovation Action Plan of the Shanghai Natural Science Fund [20ZR1409100]; Chinese Association of Integration of Traditional and Western Medicine special foundation for Obstetrics and Gynecology-PuZheng Pharmaceutical Foundation [FCK-PZ-08]; Shanghai Hospital Association [X2021046]; Special Foundation for Healthcare Research of the Shanghai Municipal Health Commission
第一作者机构:[1]The Second Clinical Medical College of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China[2]Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China[3]The Academy of Integrative Medicine of Fudan University, Shanghai, China[4]Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China
共同第一作者:
通讯作者:
通讯机构:[2]Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China[3]The Academy of Integrative Medicine of Fudan University, Shanghai, China[4]Shanghai Key Laboratory of Female Reproductive Endocrine-related Diseases, Shanghai, China[*1]Obstetrics and Gynecology Hospital of Fudan University, 419 Fangxie Road, Shanghai 200011, China.
推荐引用方式(GB/T 7714):
Pan Meijun,Pan Xinyao,Zhou Jing,et al.Update on hormone therapy for the management of postmenopausal women[J].BIOSCIENCE TRENDS.2022,16(1):46-57.doi:10.5582/bst.2021.01418.
APA:
Pan, Meijun,Pan, Xinyao,Zhou, Jing,Wang, Jing,Qi, Qing&Wang, Ling.(2022).Update on hormone therapy for the management of postmenopausal women.BIOSCIENCE TRENDS,16,(1)
MLA:
Pan, Meijun,et al."Update on hormone therapy for the management of postmenopausal women".BIOSCIENCE TRENDS 16..1(2022):46-57